USP7 and plasma cell myeloma: Since the approval of the first-in-class proteasome inhibitor bortezomib (Velcade®) by the Food and Drug Administration for treating relapsed multiple myeloma in 2003 [53], an increasing number of research institutions and pharmaceutical companies have developed simplified and efficient chemical synthesis protocols to identify compounds targeting USP7 with affinity, specificity, and stability [54, 55].